Cigna Corporation (CI) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $291.86 (-0.69%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 6, 2026 | Andrew Mok | Barclays | $303.00 | +3.8% |
| Dec 15, 2025 | Charles Rhyee | Cowen & Co. | $333.00 | +14.1% |
| Nov 4, 2025 | Scott Fidel | Goldman Sachs | $330.00 | +13.1% |
| Nov 3, 2025 | David Windley | Jefferies | $310.00 | +6.2% |
| Oct 31, 2025 | Erin Wright | Morgan Stanley | $355.00 | +21.6% |
| Oct 14, 2025 | Scott Fidel | Goldman Sachs | $370.00 | +26.8% |
| Sep 2, 2025 | David MacDonald | Truist Financial | $375.00 | +28.5% |
| Aug 14, 2025 | Michael Ha | Robert W. Baird | $372.00 | +27.5% |
| Aug 5, 2025 | George Hill | Deutsche Bank | $415.00 | +42.2% |
| May 6, 2025 | Jason Cassorla | Guggenheim | $388.00 | +32.9% |
| May 5, 2025 | Erin Wright | Morgan Stanley | $390.00 | +33.6% |
| May 5, 2025 | Andrew Mok | Barclays | $382.00 | +30.9% |
| Feb 4, 2025 | Stephen Baxter | Wells Fargo | $341.00 | +16.8% |
| Feb 3, 2025 | Jessica Tassan | Piper Sandler | $348.00 | +19.2% |
| Jan 31, 2025 | John Ransom | Raymond James | $360.00 | +23.3% |
| Jan 31, 2025 | Erin Wright | Morgan Stanley | $379.00 | +29.9% |
| Jan 31, 2025 | Ben Hendrix | RBC Capital | $355.00 | +21.6% |
| Jun 25, 2024 | Jessica Tassan | Piper Sandler | $400.00 | +37.1% |
| May 29, 2024 | Michael Ha | Robert W. Baird | $388.00 | +32.9% |
| May 6, 2024 | David Windley | Jefferies | $407.00 | +39.5% |
Top Analysts Covering CI
CI vs Sector & Market
| Metric | CI | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.14 | 2.24 | 2.40 |
| Analyst Count | 22 | 8 | 19 |
| Target Upside | +14.7% | +11475.0% | +17.1% |
| P/E Ratio | 12.38 | 3.90 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $277.90B | $282.31B | $289.85B | 11 |
| 2027-03-31 | $68.52B | $69.78B | $72.05B | 4 |
| 2027-06-30 | $72.10B | $73.43B | $75.82B | 4 |
| 2027-09-30 | $74.62B | $75.99B | $78.47B | 5 |
| 2027-12-31 | $77.46B | $78.88B | $81.45B | 4 |
| 2028-03-31 | $71.46B | $72.77B | $75.14B | 3 |
| 2028-06-30 | $75.77B | $77.17B | $79.68B | 3 |
| 2028-09-30 | $78.73B | $80.17B | $82.78B | 5 |
| 2028-12-31 | $81.57B | $83.07B | $85.77B | 3 |
| 2029-12-31 | $323.61B | $329.72B | $342.97B | 5 |
| 2030-12-31 | $325.59B | $331.74B | $345.07B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $30.03 | $30.29 | $30.57 | 15 |
| 2027-03-31 | $7.87 | $8.06 | $8.40 | 6 |
| 2027-06-30 | $8.00 | $8.19 | $8.54 | 6 |
| 2027-09-30 | $8.51 | $8.71 | $9.08 | 6 |
| 2027-12-31 | $8.26 | $8.46 | $8.82 | 6 |
| 2028-03-31 | $8.93 | $9.15 | $9.53 | 7 |
| 2028-06-30 | $9.20 | $9.43 | $9.82 | 7 |
| 2028-09-30 | $9.40 | $9.63 | $10.04 | 7 |
| 2028-12-31 | $9.05 | $9.27 | $9.66 | 7 |
| 2029-12-31 | $40.02 | $41.01 | $43.15 | 3 |
| 2030-12-31 | $44.80 | $45.90 | $48.30 | 3 |
Frequently Asked Questions
What is the analyst consensus for CI?
The consensus among 22 analysts covering Cigna Corporation (CI) is Buy with an average price target of $325.83.
What is the highest price target for CI?
The highest price target for CI is $415.00, set by George Hill at Deutsche Bank on 2025-08-05.
What is the lowest price target for CI?
The lowest price target for CI is $225.00, set by Kevin Fischbeck at Bank of America Securities on 2021-09-10.
How many analysts cover CI?
22 analysts have issued ratings for Cigna Corporation in the past 12 months.
Is CI a buy or sell right now?
Based on 22 analyst ratings, CI has a consensus rating of Buy (2.14/5) with a +14.7% upside to the consensus target of $325.83.
What are the earnings estimates for CI?
Analysts estimate CI will report EPS of $30.29 for the period ending 2026-12-31, with revenue estimated at $282.31B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.